Tezacaftor is a medication used for the treatment of cystic fibrosis. It is available in fixed-dose combination medications. The combination of tezacaftor with ivacaftor was approved for medical use in the United States in February 2018, and in Canada in 2018. Tezacaftor is a small-molecule CFTR corrector that binds nascent CFTR protein in the endoplasmic reticulum to improve folding and trafficking of certain mutant forms of the CFTR chloride channel, most notably F508del-CFTR, increasing the amount of protein delivered to the cell surface. In clinical practice it is formulated as an oral tablet in fixed-dose combinations with ivacaftor and as part of triple-combination regimens that include elexacaftor for broader mutation coverage. Key technical considerations for formulators and clinicians include its role as a corrector-class modulator, metabolism primarily via CYP3A enzymes with the potential for drug interactions, the need to match combination partner doses to mutation class and patient factors, and standard stability and handling requirements typical of modern oral small-molecule APIs.
Typical quality control for tezacaftor active pharmaceutical ingredient includes characterization of related substances by reversed-phase high-performance liquid chromatography with UV detection and orthogonal confirmation by LC-MS. A representative impurity limit set used in development and regulatory filings may specify individual identified related compounds at or below 0.2 percent weight by weight, any unspecified individual impurity not to exceed 0.05 percent, the sum of all impurities not to exceed 1.0 percent, and specific control limits for known process- and degradation-related species (for example N-oxide or dealkylated products) in the 0.05 to 0.5 percent range depending on toxicity assessment and ICH Q3A/Q3B thresholds. Specifications are validated against batch data and stability studies and may be tightened for commercial release based on toxicological qualification and regulatory requirements. Analytical method descriptions, acceptance criteria, and reporting thresholds should always follow the current regulatory dossier for the product and the manufacturer specific monograph.
Tezacaftor is used as part of modulator therapy for cystic fibrosis to correct misfolding and trafficking defects of certain CFTR mutations, and is administered only in combination formulations with potentiators such as ivacaftor or in triple combinations with elexacaftor to increase clinical benefit across specific genotypes.
Tezacaftor is a CFTR corrector. It improves folding and cellular trafficking of defective CFTR protein. Ivacaftor is a potentiator that improves ion channel gating.
Elexacaftor and tezacaftor function as complementary CFTR correctors that bind different sites on the protein to enhance folding stability and increase the amount of CFTR reaching the cell surface. Ivacaftor is a potentiator that increases the open probability of CFTR channels already at the membrane. The combined use increases the quantity of functional channels at the surface and enhances their activity, resulting in improved chloride transport compared with single agents.
